
    
      Phase IV, simple blind, 2-parallel groups, multicentric randomized trial where each patient
      will receive a single dose of the recommended by the WHO anti-flu vaccine for the 2003-2004
      period, the control group will receive it subcutaneous and intervention group intramuscular.
      The assignation to each group will be randomized. The study included 4 basic areas of
      Barcelona city. Three visits have been scheduled for each patient: moment 0, 24 hours and 10
      days after the vaccination, and a 7 month follow up period to control the incidence of the
      flu.
    
  